Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Matthew P. Challis
Observed names:
CHALLIS, MATTHEW PAUL,
Matthew Challis,
Matthew P Challis
Institution:
Monash University
Observed institutions:
Griffith University,
Deakin University,
University of Basel,
Walter and Eliza Hall Institute of Medical Research,
Monash University
ORCID:
0000-0002-9210-3095
Observed ORCID:
0000-0002-9210-3095
OpenAlex ID:
A5086096352
Multi-omic Characterization of the Mode of Action of a Potent New Antimalarial Compound, JPC-3210, Against Plasmodium falciparum
2019
·
Geoffrey W. Birrell
, Matthew P. Challis
, et al.
·
Molecular & Cellular Proteomics
·
46
Current and emerging target identification methods for novel antimalarials
2022
·
Matthew P. Challis
, Shane M. Devine
, et al.
·
International Journal for Parasitology Drugs and Drug Resistance
·
27
PDF
Discovery and development of 2-aminobenzimidazoles as potent antimalarials
2021
·
Shane M. Devine
, Matthew P. Challis
, et al.
·
European Journal of Medicinal Chemistry
·
24
Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Carlo Giannangelo
, Matthew P Challis
, et al.
·
eLife
·
8
PDF
Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Carlo Giannangelo
, Matthew P Challis
, et al.
·
eLife
·
7
On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity
2024
·
Rebecca C.S. Edgar
, Tess R. Malcolm
, et al.
·
mBio
·
6
Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon
2024
·
Yuqin Wu
, Ashish Foollee
, et al.
·
Nature Communications
·
5
PDF
Characterization of human Metaxin proteins reveals functional diversification of SAM37 homologs MTX1 and MTX3
2026
·
Sarah E. J. Morf
, Matthew P. Challis
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
PDF
Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria
2023
·
Darren Creek
, Carlo Giannangelo
, et al.
·
eLife
·
1
PDF
Proximity labelling of the BAK macropore uncovers a new role for SLC35A4-MP in mitochondrial dynamics
2026
·
Matthew P. Challis
, Stephanie M. Molé
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane
2025
·
Ghizal Siddiqui
, Carlo Giannangelo
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Author response: Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Carlo Giannangelo
, Matthew P Challis
, et al.
Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
·
eLife
Author response: Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
Reviewer #3 (Public Review): Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
Reviewer #2 (Public Review): Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
Reviewer #1 (Public Review): Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
·
Research Square
Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
·
Research Square
Reviewer #3 (Public Review): Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
Reviewer #1 (Public Review): Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria
2024
·
Darren Creek
, Carlo Giannangelo
, et al.
PDF
On-Target, Dual Aminopeptidase Inhibition Provides Cross-Species Antimalarial Activity
2023
·
Rebecca C.S. Edgar
, Tess R. Malcolm
, et al.
·
SSRN Electronic Journal
Show more works
View as search
Works count:
24
Citation count:
126
H-index:
6
I10-index:
3
Year
Topic
Type
